The BAG2 Knockout HT29 Polyclonal Cells are a genetically engineered loss-of-function model produced by CRISPR/Cas9-mediated disruption of the BAG2 gene in the human HT29 colorectal adenocarcinoma cell line. This population of polyclonal knockout cells comprises a heterogeneous mixture of alleles, enabling functional interrogation of BAG2-dependent processes without clonal selection bias. The targeted disruption depletes endogenous BAG2 expression, providing a tractable system to dissect its role in protein homeostasis, stress signaling, and tumor cell survival. Researchers can employ this tool to study BAG2??s contributions to the ubiquitin-proteasome system, chaperone networks, and apoptosis regulation, particularly in the context of colorectal cancer biology.
Derived from a primary tumor of a 44-year-old female, the HT29 cell line is a well-established model for human colorectal adenocarcinoma. These mucin-secreting epithelial cells retain many characteristics of intestinal epithelia and are widely used in cancer research, including studies of chemoresistance, signal transduction, and epithelial barrier function. Their fast proliferation and genetic stability under standard culture conditions make them suitable for high-throughput applications. As a colorectal cancer line, HT29 exhibits dysregulated pathways commonly found in advanced adenocarcinomas, offering a physiologically relevant background to assess tumor suppressor or oncogenic functions of genes like BAG2.
BAG2 functions as a co-chaperone that directly binds to HSP70 (HSPA1A) and negatively regulates its activity, thereby inhibiting the E3 ubiquitin ligase CHIP (STUB1). This suppression prevents ubiquitination and subsequent proteasomal degradation of HSP70 client proteins, including aggregation-prone substrates such as tau and mutant SOD1. Upstream, BAG2 is transcriptionally regulated by HSF1 in response to proteotoxic stress and proteasome inhibition. Downstream, it stabilizes key clients and modulates apoptosis regulators, potentially via the BCL2 family, promoting cell survival under stress. By attenuating the HSP70?CCHIP axis, BAG2 fine-tunes protein quality control and links the heat shock response to the ubiquitin-proteasome system and autophagy pathways.
In the HT29 colorectal adenocarcinoma background, BAG2 knockout is particularly relevant for dissecting mechanisms of chemoresistance and proteotoxic stress adaptation. Colorectal cancers frequently exploit co-chaperone networks to evade apoptosis induced by chemotherapeutics or proteasome inhibitors. Disruption of BAG2 in this cell line allows direct examination of how loss of BAG2 sensitizes cells to agents like MG132, alters the stability of pro- and anti-apoptotic factors, and impacts the unfolded protein response. This model also enables investigation of BAG2??s role in maintaining oncogenic signaling pathways that depend on proper protein folding and degradation, offering insights into tumor progression and therapeutic vulnerabilities.
This polyclonal knockout product is suited for a broad range of applications, including assessing proteasomal activity, monitoring ubiquitinated protein levels by western blotting, and performing cell viability assays in the presence of proteasome inhibitors. Apoptosis can be quantitated via Annexin V staining, while immunofluorescence can detect protein aggregate formation under stress. Quantitative RT-PCR can profile changes in UPR gene expression. These assays facilitate studies on protein aggregation, autophagy modulation, and apoptosis signaling. For further information or to inquire about this BAG2 knockout model, please contact Ascent Research.
